viewCB2 Insights Inc.

CB2 Insights says Premier Health begins adoption of cannabis-focused Clinical Decision Support tool

More than 4,600 physicians and other healthcare practitioners using Premier Health’s Juno electronic medical records platform will gain access to CB2's support tool

A medical professional holding marijuana plants
Practitioners will be able to draw on clinically validated data, according to CB2

CB2 Insights (CSE:CBII) said Wednesday that Premier Health Group Inc (CSE:PHGI) (OTCMKTS:PHGRF), operator of an electronic medical records platform, has begun integration of CB2’s medical cannabis Clinical Decision Support tool.

Under an agreement, more than 4,600 physicians and other healthcare practitioners using Premier Health’s Juno electronic medical records platform will gain access to what CB2 says is the only support tool of its kind. 

The support tool, according to the companies, allows physicians and other healthcare practitioners to draw on clinically validated data in order to overcome barriers they may face related to a lack of access to education, qualification factors, risks and benefits of cannabinoid therapy.

DEEP DIVE: CB2 Insights aims to be a cannabis data leader

“For the past four years, we have worked toward simplifying the process for a physician to determine the appropriateness and potential efficacy of medical cannabis as an option within a patient’s treatment plan,” CB2 CEO Prad Sekar said in a statement. “We are now in a position to benefit from the aggregated and anonymized data gathered from more than 300,000 patient visits in a clinical environment along with the hundreds of clinical trials and observational studies that are collectively used to power our CDS tool."

He added that physicians and others can use the point-of-care application to help them incorporate cannabis as a treatment option.

Toronto-based CB2, through its clinical arm in the US, operates 28 medical cannabis evaluation centers staffed with physicians and other healthcare practitioners.


CB2 Insights says it complies with the US Health Insurance Portability and Accountability Act in gathering data at the point-of-care to study trends and outcomes.

“We are dedicated to finding new ways to create value for our physician network,” said Dr. Essam Hamza, CEO of Vancouver-based Premier Health. “We continue to receive multiple requests from physicians who ask about how best to incorporate medical cannabis into their clinics. This agreement with CB2 will provide us a robust, validated tool to give our physicians and healthcare practitioners a safe and secure way to qualify, educate and, where appropriate, prescribe medical cannabis to their patients in a compliant manner.”

Share of CB2 Insights slipped C$0.02 to C$0.32 in Wednesday's Canadian trading. Premier Health was up C$0.03 to C$0.77.

–Updates share prices–

Contact Dennis Fitzgerald at dennis@proactiveinvestors.com

Quick facts: CB2 Insights Inc.

Price: 0.19 CAD

Market: CSE
Market Cap: $18.54 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CB2 Insights Inc. named herein, including the promotion by the Company of CB2 Insights Inc. in any Content on the Site, the Company receives...


Full interview: CB2 Insights announces key partnership with GL Brands for...

CB2 Insights ((CSE: CBII; OTCQB: CBIIF) CEO Prad Sekar joined Steve Darling from our Toronto studio to provide details the will begin a prospective trial with GL Brands that will assess the safety, efficacy and other health measures for patients using Green Lotus’ cannabidiol soft gel capsules...

on 17/12/19

2 min read